{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:13:51Z","timestamp":1791216831032,"version":"4.1.0"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T00:00:00Z","timestamp":1389139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0084081","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T16:50:38Z","timestamp":1389199838000},"page":"e84081","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":94,"title":["Dopamine Reduction in the Substantia Nigra of Parkinson's Disease Patients Confirmed by In Vivo Magnetic Resonance Spectroscopic Imaging"],"prefix":"10.1371","volume":"9","author":[{"given":"Adriane","family":"Gr\u00f6ger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Klose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,1,8]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"H Braak","year":"2003","journal-title":"Neurobiol Aging"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0006-8993(96)00915-8","article-title":"A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome","volume":"741","author":"M Gerlach","year":"1996","journal-title":"Brain Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/nbm.698","article-title":"Automatic quantitation of localized in vivo 1H spectra with LCModel","volume":"114","author":"SW Provencher","year":"2001","journal-title":"NMR Biomed"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/mrm.1910300604","article-title":"Estimation of metabolite concentrations from localized in vivo proton NMR spectra","volume":"30","author":"SW Provencher","year":"1993","journal-title":"Magn Reson Med"},{"key":"ref5","article-title":"Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging","author":"A Gr\u00f6ger","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1007\/s00330-011-2123-5","article-title":"Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease","volume":"21","author":"A Gr\u00f6ger","year":"2011","journal-title":"Eur Radiol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/mrm.10715","article-title":"1H NMR detection of vitamin C in human brain in vivo","volume":"51","author":"M Terpstra","year":"2004","journal-title":"Magn Reson Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.2682","article-title":"2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas","volume":"18","author":"C Choi","year":"2012","journal-title":"Nat Med"},{"key":"ref9","article-title":"Vespa: Integrated applications for RF pulse design, spectral simulation and MRS data analysis; Quebec, Canada","author":"BJ Soher","year":"2011"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/1099-1492(200005)13:3<129::AID-NBM619>3.0.CO;2-V","article-title":"Proton NMR chemical shifts and coupling constants for brain metabolites","volume":"13","author":"V Govindaraju","year":"2000","journal-title":"NMR Biomed"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/mrc.1053","article-title":"1H and 13C NMR study of 2-hydroxyglutaric acid and its lactone","volume":"40","author":"D Bal","year":"2002","journal-title":"Magn Reson Chem"},{"key":"ref12","unstructured":"Spectral Database for Organic Compounds, SDBS website. Available: http:\/\/riodb01.ibase.aist.go.jp\/sdbs\/<\/ext-link>. Accessed: 7 Sep 2012."},{"key":"ref13","unstructured":"Provencher SW (2011) LCModel & LCMgui User's Manual. LCModel Version 62\u20134. Available: http:\/\/s-provencher.com\/pub\/LCModel\/manual\/manual.pdf<\/ext-link>. Accessed: 7 Sep 2012."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e30918","DOI":"10.1371\/journal.pone.0030918","article-title":"Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS","volume":"7","author":"UE Emir","year":"2012","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0304-3940(92)90355-B","article-title":"Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease","volume":"142","author":"E Sofic","year":"1992","journal-title":"Neurosci Lett"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.nic.2009.10.001","article-title":"Anatomy of the substantia nigra and subthalamic nucleus on MR imaging","volume":"20","author":"LA Massey","year":"2010","journal-title":"Neuroimaging Clin N Am"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mrm.23001","article-title":"Longitudinal inter- and intra-individual human brain metabolic quantification over 3 years with proton MR spectroscopy at 3 T","volume":"67","author":"Kirov II","year":"2012","journal-title":"Magn Reson Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1179\/174313209X395481","article-title":"Comparative test-retest reliability of metabolite values assessed with magnetic resonance spectroscopy of the brain. The LCModel versus the manufacturer software","volume":"31","author":"N Fayed","year":"2009","journal-title":"Neurol Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1096\/fj.08-125443","article-title":"Glutathione\u2013a review on its role and significance in Parkinson's disease","volume":"23","author":"HL Martin","year":"2009","journal-title":"FASEB J"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e56501","DOI":"10.1371\/journal.pone.0056501","article-title":"Morphological and metabolic changes in the nigro-striatal pathway of synthetic proteasome inhibitor (PSI)-treated rats: a MRI and MRS study","volume":"8","author":"S Delli Pizzi","year":"2013","journal-title":"PLoS One"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0084081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T03:22:54Z","timestamp":1540005774000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0084081"}},"subtitle":[],"editor":[{"given":"Richard Jay","family":"Smeyne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,8]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0084081","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,8]]}}}